Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer

Sabra, Rayan; Billa, Nashiru; Roberts, Clive J.

Abstract

© 2019 Elsevier B.V. In the present study, we successfully developed a cetuximab-conjugated modified citrus pectin-chitosan nanoparticles for targeted delivery of curcumin (Cet-MCPCNPs) for the treatment of colorectal cancer. In vitro analyses revealed that nanoparticles were spherical with size of 249.33 ± 5.15 nm, a decent encapsulation efficiency (68.43 ± 2.4%) and a ‘smart’ drug release profile. 61.37 ± 0.70% of cetuximab was adsorbed to the surface of the nanoparticles. Cellular uptake studies displayed enhanced internalization of Cet-MCPCNPs in Caco-2 (EGFR +ve) cells, which ultimately resulted in a significant reduction in cancer cell propagation. The cell cycle analysis indicated that Cet- MCPCNPs induced cell death in enhanced percentage of Caco-2 cells by undergoing cell cycle arrest in the G2/M phase. These data suggest that Cet-MCPCNPs represent a new and promising targeting approach for the treatment of colorectal cancer.

• Journal Article Type: Article
• Acceptance Date: Oct 7, 2019
• Online Publication Date: Oct 31, 2019
• Publication Date: Dec 15, 2019
• Deposit Date: Aug 30, 2022
• Journal: International Journal of Pharmaceutics
• Print ISSN: 0378-5173
• Electronic ISSN: 1873-3476
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 572
• Article Number: 118775
• DOI: https://doi.org/10.1016/j.ijpharm.2019.118775
• Public URL: https://nottingham-repository.worktribe.com/output/3548526
• Publisher URL: https://www.sciencedirect.com/science/article/abs/pii/S0378517319308208?via%3Dihub